← Halofantrine

Patient counseling sheet

Print-ready and generated without storing patient details.

AfyaIndex · counseling handout

Halofantrine

Therapeutic agent (verify pharmacological class)

Prepared 25 Sep 2026

What it is used for

Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)). Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC. Acute P. falciparum and P. vivax.

Warnings

Excreted in milk, prolonged QTC interval, not used in cerebral malaria in com-bination with other medicine or clinical conditions, which prolong QTC interval, or patient with ventricular dysrrythmias. Consider ECG to exclude above conditions. Renal and hepatic impairment, evidence of increased CNS side effects when associated with either therapeutic or prophylactic use of chloroquine or sulphadoxine / pyrimethamine.

Possible side effects

Skin rashes, pruritus, GI disturbances, severe ventricular dysrrhythmias that may be associated with death, this risk is increased by the use of high doses or concomitant or recent use of mefloquine. AV conduction disorders or unexplained syncopal attacks.

Storage

Store as labelled. Keep out of reach of children.

No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.

AfyaIndex dataset coverage